LINGain

orange__line

Official Title: Prospective evaluation of predictive/prognostic immunogenicity biomarkers for target therapy in HER2-positive early breast cancer within the PHERGain clinical study.

The LINGain project, as a substudy of the PHERGain trial, has the potential interest to identify immunogenicity biomarkers of response or resistance linked to targeted anti-HER2 therapy. In this exploratory and comprehensive study, we hypothesize that the activation of the different subtypes of γδ T cells in peripheral blood during dual HER2 blockade with trastuzumab and pertuzumab is a signal of immune response, and it could be considered an early marker useful to predict the efficacy of biological therapy in patients with HER2-positive early breast cancer.


LINGain at clinicaltrials.gov
TUMOR TYPE PHASE N SITES COUNTRY STATUS
HER2+ EBC Sub-study 42 10 Spain Recruitment Closed